Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Jounce Therapeutics Inc (Jounce Therapeutics) is a clinical stage immunotherapy company. It develops therapies that enable the immune system to attack tumors. The company’s major pipeline products include Vopratelimab, an IgG1 monoclonal antibody that activates T cells through ICOS; JTX-8064, an LILRB2 inhibitor novel antibody; JTX-1484; target is LILRB4, pimivalimab target receptor is PD-1, GS-1811; target receptor is CCR8. Its discovery programs include LILRB1, treatment of myeloid and lymphoid cancers. Jounce offers services in the areas of tumor immunology, antibody discovery and optimization and integrated translational capabilities. The company has collaborations with the universities, general hospitals, and cancer centers. Jounce Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
780 Memorial Drive, Cambridge, Massachusetts, 02139
Website
jouncetx.com
Telephone
1 857 2593840
No of Employees
141
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$82.0M
Products and Services
| Products | Services |
|---|---|
| Vopratelimab | Tumor Immunology |
| Pimivalimab | Antibody Discovery and Optimization |
| JTX-8064 | Integrated Translating Capabilities |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Jounce Therapeutics Inc | Merck & Co Inc | Bristol-Myers Squibb Co | GSK plc | Xencor Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | United States of America |
| City | Cambridge | Rahway | Princeton | London | Pasadena |
| State/Province | Massachusetts | New Jersey | New Jersey | England | California |
| No. of Employees | 141 | 73,000 | 34,100 | 68,629 | 250 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jigar Raythatha | Chairman | Executive Board | 2022 | - |
| Richard Murray | Chief Executive Officer; Director; President | Executive Board | 2014 | 63 |
| Kim C. Drapkin | Chief Financial Officer | Senior Management | 2015 | 54 |
| Hugh Cole | Chief Operating Officer | Senior Management | - | 57 |
| Jacqui Fahey Sandell | Chief Legal Officer; Secretary | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer